S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)
S&P 500   5,020.26 (-0.04%)
DOW   37,842.79 (+0.24%)
QQQ   423.90 (-0.46%)
AAPL   167.06 (-0.56%)
MSFT   405.16 (-1.62%)
META   501.81 (+1.55%)
GOOGL   156.45 (+0.63%)
AMZN   179.42 (-1.03%)
TSLA   150.63 (-3.10%)
NVDA   847.33 (+0.83%)
AMD   154.68 (+0.43%)
NIO   4.02 (+2.81%)
BABA   68.94 (+0.17%)
T   16.28 (+0.99%)
F   12.04 (+0.00%)
MU   112.27 (-3.49%)
GE   153.93 (-1.12%)
CGC   8.01 (+23.42%)
DIS   112.88 (-0.05%)
AMC   2.92 (-2.01%)
PFE   25.37 (-0.20%)
PYPL   62.25 (-1.60%)
XOM   118.52 (-0.09%)

Cytokinetics (CYTK) Stock Price, News & Analysis

$67.02
-0.91 (-1.34%)
(As of 03:33 PM ET)
Today's Range
$66.84
$68.53
50-Day Range
$63.75
$80.99
52-Week Range
$25.98
$110.25
Volume
507,049 shs
Average Volume
3.03 million shs
Market Capitalization
$7.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.33

Cytokinetics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.87 Rating Score
Upside/​Downside
17.5% Upside
$79.33 Price Target
Short Interest
Healthy
13.33% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.83
Upright™ Environmental Score
News Sentiment
0.83mentions of Cytokinetics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$9.61 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($4.50) to ($3.17) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.85 out of 5 stars

Medical Sector

194th out of 914 stocks

Pharmaceutical Preparations Industry

67th out of 416 stocks

CYTK stock logo

About Cytokinetics Stock (NASDAQ:CYTK)

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.

CYTK Stock Price History

CYTK Stock News Headlines

Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
Cytokinetics EVP sells over $2.4m in company stock
Nvidia Has a BIG Problem — Here’s Who Benefits MOST
#1 AI Stock for 2024 Revealed In "AI Town Hall" This AI company just signed a deal with NVIDIA that went unreported by the media. Find out how you can get in on what is being dubbed 'the #1 AI stock for 2024 to buy now'
CYTK Apr 2024 60.000 call
7 Biotech Stocks Ready to Ride the Sector's Resurgence
CYTK Mar 2024 63.000 call
CYTK Mar 2024 69.000 put
CYTK Mar 2024 69.000 call
See More Headlines
Receive CYTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/27/2024
Today
4/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:CYTK
Employees
423
Year Founded
1997

Price Target and Rating

Average Stock Price Target
$79.33
High Stock Price Target
$108.00
Low Stock Price Target
$50.00
Potential Upside/Downside
+16.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.87
Research Coverage
15 Analysts

Profitability

Net Income
$-526,240,000.00
Net Margins
-6,988.63%
Pretax Margin
-6,988.63%

Debt

Sales & Book Value

Annual Sales
$7.53 million
Book Value
($3.94) per share

Miscellaneous

Free Float
100,602,000
Market Cap
$7.10 billion
Optionable
Optionable
Beta
0.68

Social Links

These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Mr. Robert I. BlumMr. Robert I. Blum (Age 60)
    CEO, President & Director
    Comp: $1.14M
  • Mr. Robert C. WongMr. Robert C. Wong (Age 56)
    VP & Chief Accounting Officer
    Comp: $463.75k
  • Dr. Fady Ibraham Malik FACC (Age 60)
    M.D., Ph.D., Executive Vice President of Research & Development
    Comp: $776.99k
  • Mr. Andrew M. Callos (Age 68)
    Executive VP & Chief Commercial Officer
    Comp: $745.4k
  • Dr. James A. Spudich Ph.D. (Age 82)
    Co-Founder & Member of Scientific Advisory Board
    Comp: $21.94k
  • Mr. Jeff Lotz
    Vice President of Sales & Operations
  • Mr. Matt Yang
    Vice President of Corporate Finance and Financial Planning & Analysis
  • Mr. Steven M. Cook (Age 65)
    Senior Vice President of Global Supply Chain Operations & Technical Operations
  • Dr. Stuart Kupfer M.D.
    Senior VP & Chief Medical Officer
  • Mr. Eric Terhaerdt
    Senior Vice President of Development Operations

CYTK Stock Analysis - Frequently Asked Questions

Should I buy or sell Cytokinetics stock right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares.
View CYTK analyst ratings
or view top-rated stocks.

What is Cytokinetics' stock price target for 2024?

15 equities research analysts have issued 1-year price targets for Cytokinetics' stock. Their CYTK share price targets range from $50.00 to $108.00. On average, they expect the company's share price to reach $79.33 in the next year. This suggests a possible upside of 17.5% from the stock's current price.
View analysts price targets for CYTK
or view top-rated stocks among Wall Street analysts.

How have CYTK shares performed in 2024?

Cytokinetics' stock was trading at $83.49 at the beginning of 2024. Since then, CYTK shares have decreased by 19.1% and is now trading at $67.52.
View the best growth stocks for 2024 here
.

Are investors shorting Cytokinetics?

Cytokinetics saw a decrease in short interest in the month of March. As of March 31st, there was short interest totaling 13,230,000 shares, a decrease of 10.6% from the March 15th total of 14,800,000 shares. Based on an average daily volume of 3,170,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 13.3% of the company's shares are sold short.
View Cytokinetics' Short Interest
.

When is Cytokinetics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CYTK earnings forecast
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) issued its earnings results on Tuesday, February, 27th. The biopharmaceutical company reported ($1.38) earnings per share for the quarter, missing the consensus estimate of ($1.03) by $0.35. The biopharmaceutical company had revenue of $1.70 million for the quarter, compared to analysts' expectations of $7.62 million. The business's revenue for the quarter was down 10.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($1.45) EPS.

What guidance has Cytokinetics issued on next quarter's earnings?

Cytokinetics issued an update on its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million.

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirador Capital Partners LP (0.03%), Los Angeles Capital Management LLC (0.02%), Wealth Enhancement Advisory Services LLC (0.01%), Cannon Global Investment Management LLC (0.01%), First Bank & Trust (0.01%) and Chemistry Wealth Management LLC (0.00%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends
.

How do I buy shares of Cytokinetics?

Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CYTK) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners